The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2023 | The use of chemotherapy in R/R Hodgkin and non-Hodgkin lymphomas
Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, compares and contrasts the use of chemotherapy in patients with relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphomas (HL; NHL). While patients with HL are increasingly being treated with novel regimens using less chemotherapy, including checkpoint inhibitors and brentuximab-based treatments, patients with NHL are usually treated with R-ICE and R-DHAP chemotherapy prior to autologous transplantation. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
